Abstract |
Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl} benzenesulfonamide ( GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.
|
Authors | Steven D Knight, Nicholas D Adams, Joelle L Burgess, Amita M Chaudhari, Michael G Darcy, Carla A Donatelli, Juan I Luengo, Ken A Newlander, Cynthia A Parrish, Lance H Ridgers, Martha A Sarpong, Stanley J Schmidt, Glenn S Van Aller, Jeffrey D Carson, Melody A Diamond, Patricia A Elkins, Christine M Gardiner, Eric Garver, Seth A Gilbert, Richard R Gontarek, Jeffrey R Jackson, Kevin L Kershner, Lusong Luo, Kaushik Raha, Christian S Sherk, Chiu-Mei Sung, David Sutton, Peter J Tummino, Ronald J Wegrzyn, Kurt R Auger, Dashyant Dhanak |
Journal | ACS medicinal chemistry letters
(ACS Med Chem Lett)
Vol. 1
Issue 1
Pg. 39-43
(Apr 08 2010)
ISSN: 1948-5875 [Print] United States |
PMID | 24900173
(Publication Type: Journal Article)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|